Research progress of iron metabolism in retinal diseases
- PMID: 37846377
- PMCID: PMC10577842
- DOI: 10.1016/j.aopr.2023.02.001
Research progress of iron metabolism in retinal diseases
Abstract
Background: Retinal diseases can lead to severe visual impairment and even blindness, but current treatments are limited. For precise targeted therapy, the pathophysiological mechanisms of the diseases still need to be further explored. Iron serves an essential role in many biological activities and helps maintain the function and morphology of the retina. The vision problems caused by retinal diseases are affecting more and more people, the study of iron metabolism in retinal diseases possesses great potential for clinical application.
Main text: Iron maintains a dynamic balance in the retina but in excess is toxic to the retina. Iron overload can lead to various pathological changes in the retina through oxidative stress, inflammation, cell death, angiogenesis and other pathways. It is therefore involved in the progression of retinal diseases such as age-related macular degeneration, glaucoma, diabetic retinopathy, retinitis pigmentosa, and hereditary iron overload. In recent years, iron chelators have been shown to be effective in the treatment of retinal diseases, but the exact mechanism is not yet fully understood. This question prompted further investigation into the specific mechanisms by which iron metabolism is involved in retinal disease.
Conclusions: This review summarizes iron metabolism processes in the retina and mechanistic studies of iron metabolism in the progression of retinal disease. It also highlights the therapeutic potential of iron chelators in retinal diseases.
Keywords: Age-related macular degeneration; Diabetic retinopathy; Glaucoma; Hereditary iron overload; Iron metabolism; Retina; Retinitis pigmentosa.
© 2023 Published by Elsevier Inc. on behalf of Zhejiang University Press.
Figures
Similar articles
-
Potential Treatment of Retinal Diseases with Iron Chelators.Pharmaceuticals (Basel). 2018 Oct 22;11(4):112. doi: 10.3390/ph11040112. Pharmaceuticals (Basel). 2018. PMID: 30360383 Free PMC article. Review.
-
Revisiting Retinal Degeneration Hallmarks: Insights from Molecular Markers and Therapy Perspectives.Int J Mol Sci. 2023 Aug 23;24(17):13079. doi: 10.3390/ijms241713079. Int J Mol Sci. 2023. PMID: 37685886 Free PMC article. Review.
-
Inflammation and retinal degenerative diseases.Neural Regen Res. 2023 Mar;18(3):513-518. doi: 10.4103/1673-5374.350192. Neural Regen Res. 2023. PMID: 36018156 Free PMC article. Review.
-
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications.Mol Neurodegener. 2022 Mar 28;17(1):25. doi: 10.1186/s13024-022-00528-w. Mol Neurodegener. 2022. PMID: 35346303 Free PMC article. Review.
-
[Visual impairment and blindness caused by posterior segment diseases in Hungary in people aged 50 years and older].Orv Hetil. 2022 Apr 17;163(16):624-630. doi: 10.1556/650.2022.32440. Print 2022 Apr 17. Orv Hetil. 2022. PMID: 35430571 Hungarian.
Cited by
-
Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management.Adv Healthc Mater. 2024 Jul;13(17):e2304626. doi: 10.1002/adhm.202304626. Epub 2024 Mar 10. Adv Healthc Mater. 2024. PMID: 38406994 Free PMC article. Review.
-
Serum Iron Status and Retinal Degenerative Diseases: A Mendelian Randomization Study on AMD, RP, and DR.Nutrients. 2024 Oct 31;16(21):3747. doi: 10.3390/nu16213747. Nutrients. 2024. PMID: 39519580 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources